Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office

Impact · against what's priced in

Phio Pharmaceuticals reports strong Phase 1b efficacy for PH-762 with a 65% pathological response rate in cSCC and a cash runway extending into H1 2027. These clinical milestones and the defined regulatory timeline for Q2 2026 provide concrete catalysts for valuation expansion.

PHIO+0.60

No priced-in read yet